UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
18. November 2014 05:44 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated
...
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
17. November 2014 08:01 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated
...
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
11. Februar 2014 09:27 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...
Overhaul of Medical Education to Address Primary Care Physician Shortage Recommended by National Panel
04. November 2013 16:00 ET
|
The Blue Ribbon Commission for the Advancement of Osteopathic Medical Education
WASHINGTON, DC--(Marketwired - Nov 4, 2013) -
News Summary:
A Blue Ribbon Commission of medical education leaders has published in a report in the November issue of Health Affairs...
MULTIMEDIA UPDATE: Experts: Steep Increase in Osteopathic Medical College Enrollment May Help Mitigate National Physician Workforce Shortage
23. Oktober 2013 15:10 ET
|
American Association of Colleges of Osteopathic Medicine
WASHINGTON, DC--(Marketwired - Oct 23, 2013) - Osteopathic medical college new student enrollment grew by 11.1 percent this year, according to data released by the American Association of Colleges...
Experts: Steep Increase in Osteopathic Medical College Enrollment May Help Mitigate National Physician Workforce Shortage
23. Oktober 2013 14:18 ET
|
American Association of Colleges of Osteopathic Medicine
WASHINGTON, DC--(Marketwired - Oct 23, 2013) - Osteopathic medical college new student enrollment grew by 11.1 percent this year, according to data released by the American Association of Colleges...
Vestiq Pharmaceuticals Offers MagBID ER Magnesium Dietary Supplement for Patients Who Have Lost Magnesium Because of Illness or Treatment With Certain Medicines
05. Juni 2013 08:00 ET
|
Vestiq Pharmaceuticals
MORRISVILLE, NC--(Marketwired - Jun 5, 2013) - Vestiq Pharmaceuticals, Inc. today announced that it will add MagBID ER (magnesium L-lactate dehydrate) tablets to its growing list of supportive...
Vestiq Pharmaceuticals Enters Into Exclusive Distribution Agreement With BMG Pharma S.r.l. for GelX(R)* Oral Gel Treatment of Oral Mucositis
05. Februar 2013 08:00 ET
|
Vestiq Pharmaceuticals
MORRISVILLE, NC--(Marketwire - Feb 5, 2013) - Vestiq Pharmaceuticals, Inc. today announced that it has taken the rights for distribution of GelX Oral Gel from BMG Pharma S.r.l. GelX is an oral...
Vestiq Pharmaceuticals, Inc. Launches With Agenda for Rapid Growth, Acquires NDAs for ORAVIG(R) (Miconazole Buccal Tablets) and Zuplenz(R) (Ondansetron) Oral Soluble Film
16. Januar 2013 08:00 ET
|
Vestiq Pharmaceuticals
MORRISVILLE, NC--(Marketwire - Jan 16, 2013) - Vestiq Pharmaceuticals, an emerging Specialty Pharmaceutical Company, formally announces its launch of products that began commercialization in...
Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin(TM) Investigational Treatment for Breast Cancer-Associated Lymphedema
15. Oktober 2012 08:00 ET
|
Laurantis Pharma Oy; Ark Therapeutics Group plc
LONDON and TURKU, FINLAND--(Marketwire - Oct 15, 2012) - Ark Therapeutics has been selected to manufacture and supply Lymfactin™ to Laurantis Pharma under a conditional agreement...